More news and press

Inscripta Launches the World’s First Benchtop Platform for Digital Genome Engineering
The Onyx platform enables scientists to create libraries of millions of precisely engineered single cells in one experiment through a fully…
Read More
Inscripta Is the Presenting Sponsor of SynBioBeta 2019
Company is launching the world’s first benchtop platform for scalable Digital Genome Engineering at the conference…
Read More
Inscripta Appoints Jim Lalonde to Lead Microbial Digital Genome Engineering Business and Portfolio Strategy
Inscripta today named Jim Lalonde, Ph.D. to its management team…
Read More
Inscripta Expands Management Team with Appointment of Three Senior Bioinformatics and Computational Biology Experts
World’s first benchtop platform for scalable digital genome engineering to be launched at SynBioBeta conference in October…
Read More
Inscripta to present first data from its digital genome engineering technology at upcoming synthetic biology conference
Results from a 200,000-edit library of an E. coli biosynthesis pathway show unprecedented scale and variety of edit types…
Read More
Inscripta Appoints Ron McGrath as Chief Financial Officer
Inscripta, developer of the first scalable platform for benchtop digital genome engineering, today announced the appointment of Ron McGrath as…
Read More
Inscripta Completes $20M Expansion of Series C Financing, Increasing Total Round to $105.5M
Continued support of existing investors will fund commercialization efforts, product launch later this year…
Read More
In the First Year of Release, Inscripta’s MAD7 CRISPR Enzyme is Widely Adopted by the Gene-Editing Community
Existing investors contribute an additional $30 million to accelerate tools that will revolutionize genomic research…
Read More
Inscripta Hires Chief Commercial Officer Jason T. Gammack to Bring Gene-Editing Tools to Market
Jason T. Gammack, 25-year veteran of life sciences commercial operations, has joined Inscripta as the company’s first chief commercial officer…
Read More
Inscripta Announces Strategic Acquisition of Solana Biosciences
Adds former Illumina operations team to develop and commercialize gene-editing technology…
Read More
1 of 2